Clinical Study
Multicenter Retrospective Analysis of the Effectiveness and Safety of Rituximab in Korean Patients with Refractory Systemic Lupus Erythematosus
Table 1
Characteristics of the 39 SLE patients receiving rituximab.
| | Age, mean ± SD years | | | Female, % | 92.1 | | Disease duration, mean ± SD years | | | Major organ involved, % () | | | Nephritis | 43.6 (17) | | Hematologic | 33.3 (13) | | Arthritis | 7.8 (3) | | Myositis | 7.8 (3) | | Vasculitis | 5.1 (2) | | Enteritis | 2.6 (1) | | Disease activity before rituximab | | | SLEDAI score, mean ± SD years | | | Anti-DNA antibody, % () | 48.7 (19) | | C3, mean ± SD g/dL | | | C4, mean ± SD g/dL | | | Rituximab administration, % () | | | 500 mg × 2 infusions | 59.0 (23) | | 1000 mg × 2 infusions | 10.3 (4) | | 375 mg/m2 × 4 infusions | 12.8 (5) | | 500 mg × 1 infusion | 7.7 (3) | | Other regimen | 10.2 (4) |
| | Previous immunosuppressive agents, % () | | | Mycophenolate mofetil | 48.7 (19) | | Cyclophosphamide | 43.6 (17) | | Azathioprine | 33.3 (13) | | Cyclosporine | 23.1 (9) | | IV immunoglobulin | 17.9 (7) | | Methotrexate | 7.7 (3) | | Tacrolimus | 2.6 (1) | | TNF blocker | 2.6 (1) | | Others | 5.1 (2) | | Number of immunosuppressive agents, mean ± SD | | | Rituximab-concomitant immunosuppressive agents, % () | | | Glucocorticoids | 87.2 (34) | | Dosage, mean ± SD mg/day | | | Hydroxychloroquine | 84.6 (33) | | Azathioprine | 59.0 (23) | | Cyclosporine | 28.2 (11) | | Mycophenolate mofetil | 23.1 (9) | | Cyclophosphamide | 2.6 (1) | | Number of immunosuppressive agents, mean ± SD | |
|
|
*Values are % (number) of patients. SLEDAI: systemic lupus erythematosus disease activity index.
|
